- A phase II trial evaluating the efficacy and safety of repeated high dose medroxyprogesterone acetate (MPA) therapy for patients with recurrent early-stage endometrial cancer or atypical endometrial hyperplasia: Japanese Gynecologic Oncology Group study (JGOG2051/KGOG2031, REMPA trial)
-
Sakai K, Yamagami W, Sato Y, Susumu N, Yokoyama Y, Takehara K, Mandai M, Okamoto A
- KMID: 2564963
- J Gynecol Oncol.
- 2024 Nov;35(6):e106.
- doi: 10.3802/jgo.2024.35.e106
Background: Fertility preserving therapy using medroxyprogesterone acetate (MPA) is an important option for young patients with endometrial cancer or atypical endometrial hyperplasia (AEH). However, the effectiveness and feasibility of repeated... -
- CITED
-
- Close
- SHARE
-
- Close
- The prognostic significance of primary tumor site in vulvar cancer: a population-based cohort study
-
Liu P, Ji X, Li Z, Kong W, Pan Z, Deng M, Miao J
- KMID: 2564959
- J Gynecol Oncol.
- 2024 Nov;35(6):e101.
- doi: 10.3802/jgo.2024.35.e101
Objective: To investigate the association of primary tumor site with prognosis in vulvar cancer, stratified by vulvar squamous cell carcinoma (SCC) and non-SCC histological types. Methods: This population-based retrospective study enrolled... -
- CITED
-
- Close
- SHARE
-
- Close
- Salvage hysterectomy for persistent residual cervical cancer: assessment of prognostic factors
-
Takekuma M, Matsuo K, Matsuzaki S, Ishikawa M, Satoh T
- KMID: 2564964
- J Gynecol Oncol.
- 2024 Nov;35(6):e113.
- doi: 10.3802/jgo.2024.35.e113
In this multicenter retrospective cohort study of 99 patients who underwent salvage hysterectomy for residual disease in the uterine cervix following the completion of definitive radiotherapy for cervical cancer across... -
- CITED
-
- Close
- SHARE
-
- Close
- Erratum: Recent breakthroughs in the management of locally advanced and recurrent/metastatic cervical cancer
-
García E, Ayoub N, Tewari KS
- KMID: 2564966
- J Gynecol Oncol.
- 2024 Nov;35(6):e118.
- doi: 10.3802/jgo.2024.35.e118
-
- CITED
-
- Close
- SHARE
-
- Close
- Cost-effectiveness analysis of simple hysterectomy compared to radical hysterectomy for early cervical cancer: analysis from the GCIG/CCTG CX.5/SHAPE trial
-
Kwon JS, McTaggart-Cowan H, Ferguson SE, Samouëlian V, Lambaudie E, Guyon F, Tidy J, Williamson K, Gleeson N, Kroon Cd, Driel Wv, Mahner S, Hanker L, Goffin F, Berger R, Eyjólfsdóttir B, Kim JW, Brotto LA, Pataky R, Yeung SS, Chan KK, Cheung MC, Ubi J, Tu D, Shepherd LE, Plante M
- KMID: 2564965
- J Gynecol Oncol.
- 2024 Nov;35(6):e117.
- doi: 10.3802/jgo.2024.35.e117
Objective: SHAPE (Simple Hysterectomy And PElvic node assessment) was an international phase III trial demonstrating that simple hysterectomy was non-inferior to radical hysterectomy for pelvic recurrence risk, but superior for... -
- CITED
-
- Close
- SHARE
-
- Close
- Prevalence and prognostic value of PD-L1 expression and tumor mutational burden in persistent, recurrent, or metastatic cervical cancer
-
Baek MH, Chen L, Tekin C, Cristescu R, Jin XY, Shao C, Ihm SY, Jelinic P, Park JY
- KMID: 2564962
- J Gynecol Oncol.
- 2024 Nov;35(6):e105.
- doi: 10.3802/jgo.2024.35.e105
Objective: To evaluate the prevalence and prognostic role of programmed death ligand 1 (PDL1) expression and tumor mutational burden (TMB) in patients with non-immunotherapytreated advanced cervical cancer. Methods: Clinical data were... -
- CITED
-
- Close
- SHARE
-
- Close
- Unveiling pembrolizumab effectiveness in diverse subtypes of MSI-high endometrial cancers
-
Ozawa R, Nishikawa T, Yoshida H, Shiraishi K, Shimoi T, Kato T, Yonemori K
- KMID: 2564961
- J Gynecol Oncol.
- 2024 Nov;35(6):e103.
- doi: 10.3802/jgo.2024.35.e103
Objective: The efficacy of pembrolizumab in patients with microsatellite instability (MSI)-high cancers has been reported; however, the differences in efficacy according to the subtypes of MSI-high endometrial cancers (ECs) remain... -
- CITED
-
- Close
- SHARE
-
- Close
- Genetic analysis of cervical cancer with lymph node metastasis
-
He H, He M, Zhou Q, Tang Y, Wang J, Li X, Zou D
- KMID: 2564960
- J Gynecol Oncol.
- 2024 Nov;35(6):e102.
- doi: 10.3802/jgo.2024.35.e102
Objective: To find out the differences in gene characteristics between cervical cancer patients with and without lymph node metastasis, and to provide reference for therapy. Methods: From January 2018 to June... -
- CITED
-
- Close
- SHARE
-
- Close
- Efficacy and safety of combined anlotinib-oral etoposide treatment for patients with platinum-resistant ovarian cancer
-
Huang S, Sheng G, Lv Q, Li Y, Meng Q, Gao X, Shang Z
- KMID: 2564958
- J Gynecol Oncol.
- 2024 Nov;35(6):e100.
- doi: 10.3802/jgo.2024.35.e100
Objective: Despite the availability of numerous treatment options, managing patients with platinum-resistant ovarian cancer (PROC) remains challenging, and the prognosis of PROC is notably unfavorable. This retrospective study aimed to... -
- CITED
-
- Close
- SHARE
-
- Close
- Cost-effectiveness analysis of single-dose or 2-dose of bivalent, quadrivalent, or nonavalent HPV vaccine in a low/middle-income country setting
-
Termrungruanglert W, Khemapech N, Vasuratna A, Havanond P, Tantitamit T
- KMID: 2564977
- J Gynecol Oncol.
- 2024 Nov;35(6):e85.
- doi: 10.3802/jgo.2024.35.e85
Objective: To compare the health impact and economic benefits among individuals who did not receive the human papillomavirus (HPV) vaccine to those who received a single dose, or 2 doses.... -
- CITED
-
- Close
- SHARE
-
- Close
- The effectiveness of CA125 and HE4 as clinical prognostic markers in epithelial ovarian cancer patients with BRCA mutation
-
Lee YJ, Kim W, Hong S, Lee YJ, Lee JY, Kim SW, Kim S, Kim YT, Nam EJ
- KMID: 2564975
- J Gynecol Oncol.
- 2024 Nov;35(6):e80.
- doi: 10.3802/jgo.2024.35.e80
Objective: To investigate the efficacy of cancer antigen 125 (CA125) and human epididymis protein 4 (HE4) in predicting survival outcomes based on breast cancer gene (BRCA) mutational status in epithelial... -
- CITED
-
- Close
- SHARE
-
- Close
- Prognostic values of tumor size and location in early stage endometrial cancer patients who received radiotherapy
-
Jiao S, Wei L, Zou L, Wang T, Hu K, Zhang F, Hou X
- KMID: 2564976
- J Gynecol Oncol.
- 2024 Nov;35(6):e84.
- doi: 10.3802/jgo.2024.35.e84
Objective: To investigate the correlation between tumor size, tumor location, and prognosis in patients with early-stage endometrial cancer (EC) receiving adjuvant radiotherapy. Methods: Data of patients who had been treated for... -
- CITED
-
- Close
- SHARE
-
- Close
- Cost-effectiveness of pembrolizumab plus chemotherapy for advanced endometrial cancer
-
Huo G, Song Y, Chen P
- KMID: 2564978
- J Gynecol Oncol.
- 2024 Nov;35(6):e86.
- doi: 10.3802/jgo.2024.35.e86
Objective: To assess the cost-effectiveness of pembrolizumab in combination with chemotherapy compared to chemotherapy alone, based on the results of the NRG-GY018 trial, in patients with advanced or recurrent endometrial... -
- CITED
-
- Close
- SHARE
-
- Close
- SLAMF7 predicts prognosis and correlates with immune infiltration in serous ovarian carcinoma
-
Deng Y, Zhang L, Dai C, Xu Y, Gan Q, Cheng J
- KMID: 2564974
- J Gynecol Oncol.
- 2024 Nov;35(6):e79.
- doi: 10.3802/jgo.2024.35.e79
Objective: Signaling lymphocytic activation molecule family members (SLAMFs) play a critical role in immune regulation of malignancies. This study aims to investigate the prognostic value and function of SLAMFs in... -
- CITED
-
- Close
- SHARE
-
- Close
- QL1604 plus paclitaxel-cisplatin/ carboplatin in patients with recurrent or metastatic cervical cancer: an open-label, single-arm, phase II trial
-
Fang C, Zhou Y, Feng Y, He L, Yu J, Li Y, Feng M, Pan M, Zhao L, Tang D, Li X, Tan B, An R, Zheng X, Si M, Zhang B, Li L, Kang X, Zhou Q, Liu J
- KMID: 2564972
- J Gynecol Oncol.
- 2024 Nov;35(6):e77.
- doi: 10.3802/jgo.2024.35.e77
Objective: QL1604 is a highly selective, humanized monoclonal antibody against programmed death protein 1. We assessed the efficacy and safety of QL1604 plus chemotherapy as first-line treatment in patients with... -
- CITED
-
- Close
- SHARE
-
- Close
- A retrospective study of dose-dense paclitaxel and carboplatin plus bevacizumab as first-line treatment of advanced epithelial ovarian cancer
-
Komazaki H, Takahashi K, Tanabe H, Shoburu Y, Kamii M, Tsuda A, Saito M, Yamada K, Takano H, Michimae H, Okamoto A
- KMID: 2564971
- J Gynecol Oncol.
- 2024 Nov;35(6):e76.
- doi: 10.3802/jgo.2024.35.e76
Objective: This study compared the effectiveness, safety, and tolerability of dose-dense paclitaxel and carboplatin plus bevacizumab (ddTC+Bev) with ddTC for advanced ovarian cancer. Methods: We retrospectively analyzed the clinical records of... -
- CITED
-
- Close
- SHARE
-
- Close
- Abnormal p53 expression is associated with poor outcomes in grade I or II, stage I, endometrioid carcinoma: a retrospective single-institute study
-
Chang YW, Kuo HL, Chen TC, Chen J, Lim L, Wang KL, Chen JR
- KMID: 2564973
- J Gynecol Oncol.
- 2024 Nov;35(6):e78.
- doi: 10.3802/jgo.2024.35.e78
Objective: The Cancer Genome Atlas study revealed an association between copy-number high (p53 abnormal) genetic mutation and poor prognosis in endometrial cancer in 2013. This retrospective study investigated outcomes in patients... -
- CITED
-
- Close
- SHARE
-
- Close
- Mirvetuximab soravtansine in platinum-resistant recurrent ovarian cancer with high folate receptor-alpha expression: a cost-effectiveness analysis
-
Zhu Y, Lin Y, Liu K, Zhu H
- KMID: 2564967
- J Gynecol Oncol.
- 2024 Nov;35(6):e71.
- doi: 10.3802/jgo.2024.35.e71
Objective: Mirvetuximab soravtansine (MIRV), a new antibody-drug conjugate, versus the investigator’s choice of chemotherapy (IC) was the first treatment to demonstrate benefits for progression-free and overall survival in platinum-resistant recurrent... -
- CITED
-
- Close
- SHARE
-
- Close
- Chemotherapy response score no longer predicts survival outcomes in high-grade serous ovarian cancer patients with BRCA mutation and/or maintenance therapy
-
Lee YJ, Shin YK, Kim NR, Kim SI, Lee YY, Park JY, Kim JW, Cho HW, Lee JY
- KMID: 2564969
- J Gynecol Oncol.
- 2024 Nov;35(6):e73.
- doi: 10.3802/jgo.2024.35.e73
Objective: We aimed to revalidate the chemotherapy response score (CRS) system as a prognostic factor for ovarian cancer patients with breast cancer gene (BRCA) mutations or those receiving frontline poly-ADP... -
- CITED
-
- Close
- SHARE
-
- Close
- Evaluation of clinical usefulness of HPV-16 and HPV-18 genotyping for cervical cancer screening
-
Cho EH, Park MS, Woo HY, Park H, Kwon MJ
- KMID: 2564968
- J Gynecol Oncol.
- 2024 Nov;35(6):e72.
- doi: 10.3802/jgo.2024.35.e72
Objective: High-risk human papillomavirus (HR-HPV) infection is a leading cause of cervical cancer, of which human papillomavirus (HPV)-16 and HPV-18 account for about 70% of cases. Since HPV infection is common,... -
- CITED
-
- Close
- SHARE
-
- Close
